IL297234A - Medical use of deridorxant - Google Patents
Medical use of deridorxantInfo
- Publication number
- IL297234A IL297234A IL297234A IL29723422A IL297234A IL 297234 A IL297234 A IL 297234A IL 297234 A IL297234 A IL 297234A IL 29723422 A IL29723422 A IL 29723422A IL 297234 A IL297234 A IL 297234A
- Authority
- IL
- Israel
- Prior art keywords
- sleep
- daridorexant
- daytime
- subject
- idsiq
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2020060940 | 2020-04-19 | ||
| PCT/EP2021/059943 WO2021213923A1 (en) | 2020-04-19 | 2021-04-16 | Medical use of daridorexant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL297234A true IL297234A (en) | 2022-12-01 |
Family
ID=75478068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL297234A IL297234A (en) | 2020-04-19 | 2021-04-16 | Medical use of deridorxant |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230134935A1 (https=) |
| EP (1) | EP4138822A1 (https=) |
| JP (1) | JP7822954B2 (https=) |
| KR (1) | KR20230004670A (https=) |
| CN (1) | CN115427037A (https=) |
| AU (1) | AU2021260018A1 (https=) |
| BR (1) | BR112022020924A2 (https=) |
| CA (1) | CA3175369A1 (https=) |
| CL (1) | CL2022002855A1 (https=) |
| IL (1) | IL297234A (https=) |
| MX (1) | MX2022011179A (https=) |
| PH (1) | PH12022552763A1 (https=) |
| TW (1) | TW202200133A (https=) |
| WO (1) | WO2021213923A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115925699B (zh) * | 2022-02-25 | 2023-10-03 | 南京知和医药科技有限公司 | 具有镇痛活性的稠环化合物及其制备方法与用途 |
| WO2024019978A2 (en) * | 2022-07-19 | 2024-01-25 | Rutgers, The State University Of New Jersey | Therapeutic combinations and methods |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013502447A (ja) * | 2009-08-24 | 2013-01-24 | グラクソ グループ リミテッド | 睡眠障害の治療のためのオレキシン受容体アンタゴニストとしての５−メチル−ピペリジン誘導体 |
| ES2617863T3 (es) | 2012-06-04 | 2017-06-20 | Actelion Pharmaceuticals Ltd. | Derivados de bencimidazol-prolina |
| MY179862A (en) | 2013-12-03 | 2020-11-18 | Idorsia Pharmaceuticals Ltd | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists |
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| SI3077391T1 (sl) | 2013-12-04 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Uporaba benzimidazol-prolinskih derivatov |
| ES2843952T3 (es) | 2014-10-23 | 2021-07-21 | Eisai R&D Man Co Ltd | Composiciones para tratar el insomnio |
| LT3619199T (lt) | 2017-05-03 | 2021-09-27 | Idorsia Pharmaceuticals Ltd | 2-([1,2,3]triazol-2-il)-benzenkarboksirūgšties darinių gamyba |
-
2021
- 2021-04-16 EP EP21718142.9A patent/EP4138822A1/en active Pending
- 2021-04-16 WO PCT/EP2021/059943 patent/WO2021213923A1/en not_active Ceased
- 2021-04-16 IL IL297234A patent/IL297234A/en unknown
- 2021-04-16 PH PH1/2022/552763A patent/PH12022552763A1/en unknown
- 2021-04-16 BR BR112022020924A patent/BR112022020924A2/pt not_active Application Discontinuation
- 2021-04-16 KR KR1020227040124A patent/KR20230004670A/ko active Pending
- 2021-04-16 AU AU2021260018A patent/AU2021260018A1/en active Pending
- 2021-04-16 US US17/996,499 patent/US20230134935A1/en active Pending
- 2021-04-16 CN CN202180028992.7A patent/CN115427037A/zh active Pending
- 2021-04-16 JP JP2022563036A patent/JP7822954B2/ja active Active
- 2021-04-16 CA CA3175369A patent/CA3175369A1/en active Pending
- 2021-04-16 MX MX2022011179A patent/MX2022011179A/es unknown
- 2021-04-19 TW TW110113975A patent/TW202200133A/zh unknown
-
2022
- 2022-10-17 CL CL2022002855A patent/CL2022002855A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3175369A1 (en) | 2021-10-28 |
| TW202200133A (zh) | 2022-01-01 |
| JP2023521492A (ja) | 2023-05-24 |
| BR112022020924A2 (pt) | 2023-02-14 |
| AU2021260018A1 (en) | 2022-12-22 |
| MX2022011179A (es) | 2022-10-07 |
| WO2021213923A1 (en) | 2021-10-28 |
| KR20230004670A (ko) | 2023-01-06 |
| JP7822954B2 (ja) | 2026-03-03 |
| US20230134935A1 (en) | 2023-05-04 |
| EP4138822A1 (en) | 2023-03-01 |
| CL2022002855A1 (es) | 2023-06-02 |
| CN115427037A (zh) | 2022-12-02 |
| PH12022552763A1 (en) | 2024-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025036703A (ja) | 不安障害、頭痛障害、及び摂食障害をサイロシビンで治療するための方法 | |
| Porwal et al. | An update on assessment, therapeutic management, and patents on insomnia | |
| TW200403997A (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | |
| AU2018383098B2 (en) | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions | |
| IL294485A (en) | Reduction of side effects of nmda antagonists | |
| US12485100B2 (en) | Treatment of menstrual cycle-induced symptoms | |
| MacDonald et al. | Current therapies and drug development pipeline in lewy body dementia: an update | |
| JP7822954B2 (ja) | ダリドレキサントの医学的用途 | |
| Winkelman et al. | Current patterns and future directions in the treatment of insomnia | |
| TW201211021A (en) | Methods of use of cyclic amide derivatives to treat schizophrenia | |
| Thakur et al. | Clinical manual of geriatric psychiatry | |
| EA051128B1 (ru) | Медицинское применение даридорексанта | |
| Collins et al. | Pediatric cancer pain | |
| Brown et al. | Psychiatric disorders | |
| Gowan et al. | Disease state management: Anticholinergic medicines-practice considerations and alternatives | |
| HK40112834A (zh) | 用於痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗 | |
| Gowan et al. | Anticholinergic medicines: practice considerations and alternatives. | |
| Neubauer | Effective Ways to Manage Insomnia: Improving Outcomes through Optimal Treatment Strategies | |
| Rutkofsky et al. | Gabapentin for Post-Hospitalization Alcohol Relapse Prevention; Should Gabapentin Be Considered for FDA Approval in the Treatment of Alcohol Use Disorder?: A Case Presentation and Literature Review | |
| JP2023520016A (ja) | 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン | |
| HK40068314A (en) | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | |
| TRULLÀS | Use of MDMA in the treatment of Post-traumatic Stress Disorder | |
| HK40032890A (en) | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions | |
| Neubauer et al. | Pharmacological Management of Insomnia | |
| REINEMER | APPROVED BY THE GRADUATE COUNCIL, COLLEGE^ PF—DENTISTRY:(signed) _ f Assistant Dean of Research and Advanced Education APPROVED BY THE GRADUATE COUNCIL |